Genetic and pharmacological strategies to refunctionalize the von hippel lindau R167Q mutant protein

Zhiyong Ding, Peter German, Shanshan Bai, A. Srinivas Reddy, Xian De Liu, Mianen Sun, Lijun Zhou, Xiaohua Chen, Xiaobei Zhao, Chengbiao Wu, Shuxing Zhang, Gordon Mills, Eric Jonasch

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aberrant von Hippel Lindau (VHL) protein function is the underlying driver of VHL-related diseases, including both sporadic and inherited clear cell renal cell carcinoma (ccRCC). About one third of VHL mutations are missense point mutations, with R167Q being the most common VHL point mutation in hereditary VHL disease. Although it has been studied extensively, the ability of VHL-R167Q to downregulate hypoxia-inducible factor 2a (HIF2a) is still controversial. In addition, the manner in which the mutation contributes to tumorigenesis is not fully understood. No therapeutic approach is available to target VHL-R167Q and similar missense point mutations. We analyzed VHL-R167Q proteostasis and function at normoxia, at hypoxia with different oxygen pressure, and in a xenograft mouse model. We showed that the protein levels of VHL-R167Q dictate its ability to downregulate HIF2a and suppress tumor growth. Strikingly, the proteasome inhibitors bortezomib and carfilzomib, which are currently in clinical use, stabilize VHL-R167Q and increase its ability to downregulate HIF2a. VHL-R167Q binds elongin C and elongin B with considerably less avidity than wild-type VHL does but retains residual capacity to generate a VHL-elongin C-elongin B complex, downregulate HIF2a, and suppress tumorigenesis, which could be rescued by increase of VHL-R167Q levels. Finally, we used in silico approaches and identified other missense VHL mutants in addition to VHL-R167Q that might be rescued by similar strategies. Thus, our studies revealed detailed information describing how VHL-R167Q contributes to tumorigenesis and identified a potential targeted therapy for ccRCC and other VHL-related disease in patients carrying VHL-R167Q or similar missense mutations.

Original languageEnglish (US)
Pages (from-to)3127-3136
Number of pages10
JournalCancer Research
Volume74
Issue number11
DOIs
StatePublished - Jun 1 2014
Externally publishedYes

Fingerprint

Mutant Proteins
von Hippel-Lindau Disease
Pharmacology
Missense Mutation
Down-Regulation
Point Mutation
Carcinogenesis
Renal Cell Carcinoma
Mutation
Proteasome Inhibitors
Heterografts
Computer Simulation
Proteins
Hypoxia
Oxygen
Pressure
elongin
Therapeutics
Growth
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ding, Z., German, P., Bai, S., Reddy, A. S., Liu, X. D., Sun, M., ... Jonasch, E. (2014). Genetic and pharmacological strategies to refunctionalize the von hippel lindau R167Q mutant protein. Cancer Research, 74(11), 3127-3136. https://doi.org/10.1158/0008-5472.CAN-13-3213

Genetic and pharmacological strategies to refunctionalize the von hippel lindau R167Q mutant protein. / Ding, Zhiyong; German, Peter; Bai, Shanshan; Reddy, A. Srinivas; Liu, Xian De; Sun, Mianen; Zhou, Lijun; Chen, Xiaohua; Zhao, Xiaobei; Wu, Chengbiao; Zhang, Shuxing; Mills, Gordon; Jonasch, Eric.

In: Cancer Research, Vol. 74, No. 11, 01.06.2014, p. 3127-3136.

Research output: Contribution to journalArticle

Ding, Z, German, P, Bai, S, Reddy, AS, Liu, XD, Sun, M, Zhou, L, Chen, X, Zhao, X, Wu, C, Zhang, S, Mills, G & Jonasch, E 2014, 'Genetic and pharmacological strategies to refunctionalize the von hippel lindau R167Q mutant protein', Cancer Research, vol. 74, no. 11, pp. 3127-3136. https://doi.org/10.1158/0008-5472.CAN-13-3213
Ding, Zhiyong ; German, Peter ; Bai, Shanshan ; Reddy, A. Srinivas ; Liu, Xian De ; Sun, Mianen ; Zhou, Lijun ; Chen, Xiaohua ; Zhao, Xiaobei ; Wu, Chengbiao ; Zhang, Shuxing ; Mills, Gordon ; Jonasch, Eric. / Genetic and pharmacological strategies to refunctionalize the von hippel lindau R167Q mutant protein. In: Cancer Research. 2014 ; Vol. 74, No. 11. pp. 3127-3136.
@article{f7f35cc6b9ac4d88974381807edb73a3,
title = "Genetic and pharmacological strategies to refunctionalize the von hippel lindau R167Q mutant protein",
abstract = "Aberrant von Hippel Lindau (VHL) protein function is the underlying driver of VHL-related diseases, including both sporadic and inherited clear cell renal cell carcinoma (ccRCC). About one third of VHL mutations are missense point mutations, with R167Q being the most common VHL point mutation in hereditary VHL disease. Although it has been studied extensively, the ability of VHL-R167Q to downregulate hypoxia-inducible factor 2a (HIF2a) is still controversial. In addition, the manner in which the mutation contributes to tumorigenesis is not fully understood. No therapeutic approach is available to target VHL-R167Q and similar missense point mutations. We analyzed VHL-R167Q proteostasis and function at normoxia, at hypoxia with different oxygen pressure, and in a xenograft mouse model. We showed that the protein levels of VHL-R167Q dictate its ability to downregulate HIF2a and suppress tumor growth. Strikingly, the proteasome inhibitors bortezomib and carfilzomib, which are currently in clinical use, stabilize VHL-R167Q and increase its ability to downregulate HIF2a. VHL-R167Q binds elongin C and elongin B with considerably less avidity than wild-type VHL does but retains residual capacity to generate a VHL-elongin C-elongin B complex, downregulate HIF2a, and suppress tumorigenesis, which could be rescued by increase of VHL-R167Q levels. Finally, we used in silico approaches and identified other missense VHL mutants in addition to VHL-R167Q that might be rescued by similar strategies. Thus, our studies revealed detailed information describing how VHL-R167Q contributes to tumorigenesis and identified a potential targeted therapy for ccRCC and other VHL-related disease in patients carrying VHL-R167Q or similar missense mutations.",
author = "Zhiyong Ding and Peter German and Shanshan Bai and Reddy, {A. Srinivas} and Liu, {Xian De} and Mianen Sun and Lijun Zhou and Xiaohua Chen and Xiaobei Zhao and Chengbiao Wu and Shuxing Zhang and Gordon Mills and Eric Jonasch",
year = "2014",
month = "6",
day = "1",
doi = "10.1158/0008-5472.CAN-13-3213",
language = "English (US)",
volume = "74",
pages = "3127--3136",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Genetic and pharmacological strategies to refunctionalize the von hippel lindau R167Q mutant protein

AU - Ding, Zhiyong

AU - German, Peter

AU - Bai, Shanshan

AU - Reddy, A. Srinivas

AU - Liu, Xian De

AU - Sun, Mianen

AU - Zhou, Lijun

AU - Chen, Xiaohua

AU - Zhao, Xiaobei

AU - Wu, Chengbiao

AU - Zhang, Shuxing

AU - Mills, Gordon

AU - Jonasch, Eric

PY - 2014/6/1

Y1 - 2014/6/1

N2 - Aberrant von Hippel Lindau (VHL) protein function is the underlying driver of VHL-related diseases, including both sporadic and inherited clear cell renal cell carcinoma (ccRCC). About one third of VHL mutations are missense point mutations, with R167Q being the most common VHL point mutation in hereditary VHL disease. Although it has been studied extensively, the ability of VHL-R167Q to downregulate hypoxia-inducible factor 2a (HIF2a) is still controversial. In addition, the manner in which the mutation contributes to tumorigenesis is not fully understood. No therapeutic approach is available to target VHL-R167Q and similar missense point mutations. We analyzed VHL-R167Q proteostasis and function at normoxia, at hypoxia with different oxygen pressure, and in a xenograft mouse model. We showed that the protein levels of VHL-R167Q dictate its ability to downregulate HIF2a and suppress tumor growth. Strikingly, the proteasome inhibitors bortezomib and carfilzomib, which are currently in clinical use, stabilize VHL-R167Q and increase its ability to downregulate HIF2a. VHL-R167Q binds elongin C and elongin B with considerably less avidity than wild-type VHL does but retains residual capacity to generate a VHL-elongin C-elongin B complex, downregulate HIF2a, and suppress tumorigenesis, which could be rescued by increase of VHL-R167Q levels. Finally, we used in silico approaches and identified other missense VHL mutants in addition to VHL-R167Q that might be rescued by similar strategies. Thus, our studies revealed detailed information describing how VHL-R167Q contributes to tumorigenesis and identified a potential targeted therapy for ccRCC and other VHL-related disease in patients carrying VHL-R167Q or similar missense mutations.

AB - Aberrant von Hippel Lindau (VHL) protein function is the underlying driver of VHL-related diseases, including both sporadic and inherited clear cell renal cell carcinoma (ccRCC). About one third of VHL mutations are missense point mutations, with R167Q being the most common VHL point mutation in hereditary VHL disease. Although it has been studied extensively, the ability of VHL-R167Q to downregulate hypoxia-inducible factor 2a (HIF2a) is still controversial. In addition, the manner in which the mutation contributes to tumorigenesis is not fully understood. No therapeutic approach is available to target VHL-R167Q and similar missense point mutations. We analyzed VHL-R167Q proteostasis and function at normoxia, at hypoxia with different oxygen pressure, and in a xenograft mouse model. We showed that the protein levels of VHL-R167Q dictate its ability to downregulate HIF2a and suppress tumor growth. Strikingly, the proteasome inhibitors bortezomib and carfilzomib, which are currently in clinical use, stabilize VHL-R167Q and increase its ability to downregulate HIF2a. VHL-R167Q binds elongin C and elongin B with considerably less avidity than wild-type VHL does but retains residual capacity to generate a VHL-elongin C-elongin B complex, downregulate HIF2a, and suppress tumorigenesis, which could be rescued by increase of VHL-R167Q levels. Finally, we used in silico approaches and identified other missense VHL mutants in addition to VHL-R167Q that might be rescued by similar strategies. Thus, our studies revealed detailed information describing how VHL-R167Q contributes to tumorigenesis and identified a potential targeted therapy for ccRCC and other VHL-related disease in patients carrying VHL-R167Q or similar missense mutations.

UR - http://www.scopus.com/inward/record.url?scp=84902170698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902170698&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-3213

DO - 10.1158/0008-5472.CAN-13-3213

M3 - Article

C2 - 24755468

AN - SCOPUS:84902170698

VL - 74

SP - 3127

EP - 3136

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 11

ER -